Repetitive Intermittent Hyperglycemia Drives the M1 Polarization and Inflammatory Responses in THP-1 Macrophages Through the Mechanism Involving the TLR4-IRF5 Pathway.


Journal

Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052

Informations de publication

Date de publication:
12 08 2020
Historique:
received: 05 07 2020
revised: 08 08 2020
accepted: 10 08 2020
entrez: 19 8 2020
pubmed: 19 8 2020
medline: 20 3 2021
Statut: epublish

Résumé

Repetitive intermittent hyperglycemia (RIH) is an independent risk factor for complications associated with type-2 diabetes (T2D). Glucose fluctuations commonly occur in T2D patients with poor glycemic control or following intensive therapy. Reducing blood glucose as well as glucose fluctuations is critical to the control of T2D and its macro-/microvascular complications. The interferon regulatory factor (IRF)-5 located downstream of the nutrient sensor toll-like receptor (TLR)-4, is emerging as a key metabolic regulator. It remains unclear how glucose fluctuations may alter the IRF5/TLR4 expression and inflammatory responses in monocytes/macrophages. To investigate this, first, we determined IRF5 gene expression by real-time qRT-PCR in the white adipose tissue samples from 39 T2D and 48 nondiabetic individuals. Next, we cultured THP-1 macrophages in hypo- and hyperglycemic conditions and compared, at the protein and transcription levels, the expressions of IRF5, TLR4, and M1/M2 polarization profile and inflammatory markers against control (normoglycemia). Protein expression was assessed using flow cytometry, ELISA, Western blotting, and/or confocal microscopy. IRF5 silencing was achieved by small interfering RNA (siRNA) transfection. The data show that adipose IRF5 gene expression was higher in T2D than nondiabetic counterparts (P = 0.006), which correlated with glycated hemoglobin (HbA1c) (r = 0.47/P < 0.001), homeostatic model assessment of insulin resistance (HOMA-IR) (r = 0.23/P = 0.03), tumor necrosis factor (TNF)-α (r = 0.56/P < 0.0001), interleukin (IL)-1β (r = 0.40/P = 0.0009), and C-C motif chemokine receptor (CCR)-2 (r = 0.49/P < 0.001) expression. IRF5 expression in macrophages was induced/upregulated (P < 0.05) by hypoglycemia (3 mM/L), persistent hyperglycemia (15 mM/L-25 mM/L), and RIH/glucose fluctuations (3-15 mM/L) as compared to normoglycemia (5 mM/L). RIH/glucose fluctuations also induced M1 polarization and an inflammatory profile (CD11c, IL-1β, TNF-α, IL-6, and monocyte chemoattractant protein (MCP)-1) in macrophages. RIH/glucose fluctuations also drove the expression of matrix metalloproteinase (MMP)-9 (P < 0.001), which is a known marker for cardiovascular complication in T2D patients. Notably, all these changes were counteracted by IRF5 silencing in macrophages. In conclusion, RIH/glucose fluctuations promote the M1 polarization and inflammatory responses in macrophages via the mechanism involving TLR4-IRF5 pathway, which may have significance for metabolic inflammation.

Identifiants

pubmed: 32806763
pii: cells9081892
doi: 10.3390/cells9081892
pmc: PMC7463685
pii:
doi:

Substances chimiques

IRF5 protein, human 0
Interferon Regulatory Factors 0
RNA, Small Interfering 0
TLR4 protein, human 0
Toll-Like Receptor 4 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Références

Oncogene. 2002 Apr 25;21(18):2914-8
pubmed: 11973653
J Pain Res. 2018 Sep 07;11:1769-1778
pubmed: 30237731
Cell Metab. 2008 Jan;7(1):86-94
pubmed: 18177728
Metabolism. 2016 Dec;65(12):1695-1705
pubmed: 27832858
Cell Metab. 2014 May 6;19(5):821-35
pubmed: 24807222
Diabetes. 2010 Jul;59(7):1648-56
pubmed: 20357360
Cell Metab. 2014 Jan 7;19(1):162-171
pubmed: 24374218
Diabetes. 2008 Nov;57(11):3090-8
pubmed: 18650365
Sci Immunol. 2020 May 22;5(47):
pubmed: 32444476
Biochem Biophys Res Commun. 2005 Sep 23;335(2):491-5
pubmed: 16084832
Acta Med Indones. 2014 Apr;46(2):83-9
pubmed: 25053679
Pol Arch Intern Med. 2019 Jun 28;129(6):370-376
pubmed: 31169264
Hum Mol Genet. 2007 Dec 15;16(24):3008-16
pubmed: 17881657
Front Immunol. 2014 Sep 26;5:470
pubmed: 25309549
Cells. 2019 Nov 11;8(11):
pubmed: 31718015
Cells. 2020 Mar 16;9(3):
pubmed: 32188105
J Immunol. 2018 May 15;200(10):3599-3611
pubmed: 29632147
Diabetol Metab Syndr. 2015 Oct 13;7:89
pubmed: 26468333
Acta Diabetol. 2017 Aug;54(8):727-736
pubmed: 28478520
Nat Immunol. 2011 Mar;12(3):231-8
pubmed: 21240265
J Inflamm (Lond). 2015 Apr 18;12:32
pubmed: 25931987
Cell Physiol Biochem. 2019;52(4):908-921
pubmed: 30964608
J Clin Endocrinol Metab. 2011 Aug;96(8):2367-76
pubmed: 21593112
Middle East Afr J Ophthalmol. 2012 Jan;19(1):70-4
pubmed: 22346117
Front Immunol. 2016 Jan 05;6:637
pubmed: 26779183
Shock. 2001 Feb;15(2):135-42
pubmed: 11220642
J Inflamm (Lond). 2016 Apr 22;13:13
pubmed: 27110221
Diabet Med. 2010 Aug;27(8):872-8
pubmed: 20653743
Bioessays. 2019 May;41(5):e1800260
pubmed: 30970156
Biomolecules. 2019 Oct 01;9(10):
pubmed: 31581558
Mol Cell Biochem. 2010 Oct;343(1-2):27-35
pubmed: 20524146
J Biol Chem. 2005 Apr 29;280(17):17005-12
pubmed: 15695821
Cell Physiol Biochem. 2017;41(5):1993-2003
pubmed: 28419983
Proc Natl Acad Sci U S A. 2015 Dec 8;112(49):15136-41
pubmed: 26598674
J Clin Invest. 2006 Nov;116(11):3015-25
pubmed: 17053832
Int J Mol Sci. 2019 Sep 19;20(18):
pubmed: 31546972
Arterioscler Thromb Vasc Biol. 2006 Oct;26(10):2275-80
pubmed: 16888238
Blood. 2010 Jun 3;115(22):4421-30
pubmed: 20237317
Cardiovasc Diabetol. 2013 Jan 02;12:1
pubmed: 23280391
Diabetes Care. 2014 Aug;37(8):2359-65
pubmed: 24812434
J Clin Invest. 2016 Aug 1;126(8):2839-54
pubmed: 27400129
Open Access Maced J Med Sci. 2018 Nov 18;6(11):2067-2072
pubmed: 30559862
Nature. 2005 Mar 10;434(7030):243-9
pubmed: 15665823
Pharmacotherapy. 2005 Jul;25(7):963-76
pubmed: 16006275
Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3402-7
pubmed: 17360658
Diabetes. 2003 Nov;52(11):2795-804
pubmed: 14578299
Diabetes. 2017 Apr;66(4):1052-1061
pubmed: 28115398
J Immunol. 2010 Jul 1;185(1):605-14
pubmed: 20498354
Diabetes Care. 2008 Oct;31(10):2032-7
pubmed: 18591400
J Cereb Blood Flow Metab. 1998 Nov;18(11):1163-72
pubmed: 9809504
Nat Rev Immunol. 2013 Sep;13(9):649-65
pubmed: 23969736
Mucosal Immunol. 2019 Jul;12(4):888-896
pubmed: 31086271
Anesth Analg. 2017 Jan;124(1):35-41
pubmed: 27749341
JAMA. 2006 Apr 12;295(14):1681-7
pubmed: 16609090
BMC Immunol. 2018 Jul 11;19(1):24
pubmed: 29996768
JAMA. 2006 Apr 12;295(14):1707-8
pubmed: 16609094
Immunology. 2010 Apr;129(4):516-24
pubmed: 20002786
J Interferon Cytokine Res. 2002 Jan;22(1):59-71
pubmed: 11846976
Diabetes Care. 2010 Feb;33(2):428-33
pubmed: 20103558
Nat Med. 2015 Jun;21(6):610-8
pubmed: 25939064
Diabetologia. 1999 Sep;42(9):1113-9
pubmed: 10447524
Atherosclerosis. 2010 May;210(1):302-6
pubmed: 20005514
Blood. 2008 Sep 15;112(6):2360-8
pubmed: 18583567
Cell Physiol Biochem. 2016;39(3):889-900
pubmed: 27497609
Clin Immunol. 2014 Aug;153(2):343-52
pubmed: 24928322
Can J Neurol Sci. 2014 Jul;41(4):486-92
pubmed: 24878474
Indian J Endocrinol Metab. 2013 Sep;17(5):819-34
pubmed: 24083163
Crit Care Med. 2008 Aug;36(8):2316-21
pubmed: 18596625
Cells. 2020 May 11;9(5):
pubmed: 32403230
Diabet Med. 2010 Aug;27(8):862-7
pubmed: 20653741
Front Immunol. 2014 Nov 28;5:614
pubmed: 25506346
Mediators Inflamm. 2013;2013:245804
pubmed: 24453413
Eur J Endocrinol. 2006 Feb;154(2):311-7
pubmed: 16452546
Int J Mol Sci. 2019 Oct 02;20(19):
pubmed: 31581657
Immunol Lett. 2016 Aug;176:81-9
pubmed: 27269375
Med Sci (Paris). 2015 Dec;31(12):1080-2
pubmed: 26672660
Crit Care Med. 2010 Mar;38(3):838-42
pubmed: 20035218
Front Endocrinol (Lausanne). 2020 Jul 07;11:514
pubmed: 32733388
Cardiovasc Diabetol. 2016 May 21;15:79
pubmed: 27208906
Diabetes. 2005 Jun;54(6):1615-25
pubmed: 15919781
Circ Res. 2001 Jun 22;88(12):1291-8
pubmed: 11420306

Auteurs

Fatema Al-Rashed (F)

Immunology & Microbiology Department, Dasman Diabetes Institute, Kuwait City 15462, Kuwait.
Kuwait Ministry of Health, Immunology Unit, Mubarak Al Kabeer Hospital, Kuwait City 30000, Kuwait.

Sardar Sindhu (S)

Animal & Imaging Core Facility, Dasman Diabetes Institute, Kuwait City 15462, Kuwait.

Hossein Arefanian (H)

Immunology & Microbiology Department, Dasman Diabetes Institute, Kuwait City 15462, Kuwait.

Ashraf Al Madhoun (A)

Animal & Imaging Core Facility, Dasman Diabetes Institute, Kuwait City 15462, Kuwait.
Genetics and Bioinformatics Department, Dasman Diabetes Institute, Kuwait City 15462, Kuwait.

Shihab Kochumon (S)

Immunology & Microbiology Department, Dasman Diabetes Institute, Kuwait City 15462, Kuwait.

Reeby Thomas (R)

Immunology & Microbiology Department, Dasman Diabetes Institute, Kuwait City 15462, Kuwait.

Sarah Al-Kandari (S)

Immunology & Microbiology Department, Dasman Diabetes Institute, Kuwait City 15462, Kuwait.

Abdulwahab Alghaith (A)

School of Medicine, Royal College of Surgeons, D02 YN77 Dublin 2, Ireland.

Texy Jacob (T)

Immunology & Microbiology Department, Dasman Diabetes Institute, Kuwait City 15462, Kuwait.

Fahd Al-Mulla (F)

Genetics and Bioinformatics Department, Dasman Diabetes Institute, Kuwait City 15462, Kuwait.

Rasheed Ahmad (R)

Immunology & Microbiology Department, Dasman Diabetes Institute, Kuwait City 15462, Kuwait.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH